drugset
drugset / Trial / NCT07476014

Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07476014 ↗

Phase 0 Not yet recruiting 18 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelPrevention

Summary

This study is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial. Subjects will be recipients of allogeneic hematopoietic stem cell transplantation, with a planned enrollment of 9 to 18 subjects, to evaluate the safety and efficacy of JYEST cell injection for the prevention of EBV infection after allogeneic hematopoietic stem cell transplantation.

Timeline

Start
2026-02-28
Primary completion
2029-01-01
Completion
2029-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject JYEST cell injection Cell therapy 5e+07 cells Intravenous
Subject JYEST cell injection Cell therapy 1e+08 cells Intravenous
Subject JYEST cell injection Cell therapy 2e+08 cells Intravenous

Indications

disease related to hematopoietic stem cell transplant